A phase I study of modified irinotecan (CPT-11) plus cisplatin (CDDP) [m-IP] against paclitaxel/carboplatin [TC] -resistant and recurrent ovarian cancer

Takahiro Suzuki,M. Morishita,Motoki Matsuura,T. Fujimoto,Ryoichi Tanaka,Eiki Ito,Y. Ebina,Tsuyoshi Saito

A phase I study of modified irinotecan (CPT-11) plus cisplatin (CDDP) [m-IP] against paclitaxel/carboplatin [TC] -resistant and recurrent ovarian cancer

2016

Takahiro Suzuki
M. Morishita
Motoki Matsuura
T. Fujimoto
Ryoichi Tanaka
Eiki Ito
Y. Ebina
Tsuyoshi Saito

13015 Background: CPT-11/CDDP is effective regimen for ovarian cancer. Particularly against ovarian cancer resistant to prior chemotherapy, a 40% response rate was reported (Sugiyama T Cancer Lette...

Keywords:

Oncology
Irinotecan
Internal medicine
Pathology
Cisplatin
Paclitaxel carboplatin
Cancer
Recurrent Ovarian Cancer
Chemotherapy
Regimen
Ovarian cancer
Medicine
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations